Endocrine Pharmacology Practice Questions

Q: Intranasal calcitonin is used for:

Osteoporosis (Post-menopausal). ***Osteoporosis (Post-menopausal)*** - **Calcitonin** inhibits osteoclast activity, reducing bone resorption and slowing bone loss, which is particularly beneficial in **post-menopausal osteoporosis**. - Intranasal calcitonin is approved for the treatment of **post-menopausal osteoporosis** in women who are at least 5 years past menopause. *Osteoporosis (Senile)* - While calcitonin can have some effect, it is generally **less effective** for senile osteoporosis compared to other agents like bisphosphonates. - Senile osteoporosis primarily results from **age-related bone formation decrease** rather than solely increased bone resorption. *Paget's disease* - **Calcitonin** can be used in Paget's disease to reduce bone turnover and pain, but it is **not the first-line treatment**, and bisphosphonates are generally more effective. - Paget's disease involves disorganized bone remodeling, and while calcitonin helps, it's not the primary indication for the intranasal form. *Hypercalcemia* - **Calcitonin** can acutely lower **serum calcium levels** by inhibiting osteoclast activity and promoting renal calcium excretion. - However, for sustained management of severe hypercalcemia, other interventions like hydration, diuretics, and bisphosphonates are typically more effective and primary treatments.

Q: What is the longest-acting insulin?

Degludec insulin. ***Degludec insulin*** - Degludec insulin is an **ultra-long-acting insulin analog**, providing a duration of action of up to 42 hours, making it the longest-acting available. - Its prolonged action is due to the formation of soluble **multihexamers** in the subcutaneous tissue, which slowly release insulin monomers into the circulation. *Insulin-zinc suspension* - This refers to older formulations like **Lente** and **Ultralente** insulins, which had intermediate to long durations, but not as long as modern ultra-long-acting insulins. - While prolonged compared to regular insulin, their duration of action was typically around 24-36 hours, making them shorter-acting than degludec. *Neutral protamine Hagedorn (NPH)* - NPH is an **intermediate-acting insulin** with a duration of action usually between 10-18 hours. - Its action profile involves a peak, and it typically requires twice-daily dosing, unlike ultra-long-acting insulins. *Protamine-zinc insulin* - This is an older, **long-acting insulin** formulation that had a duration of action around 24-36 hours. - It has largely been replaced by newer, more predictable basal insulins like glargine and degludec due to issues with variability in absorption.

Q: Which of the following drugs used to treat type II diabetes mellitus causes weight loss?

Metformin. ***Metformin*** - **Metformin** often leads to **modest weight loss** as it improves insulin sensitivity and reduces hepatic glucose production. - It works by activating **AMPK**, which can suppress appetite and reduce fat storage. *Glimepiride* - **Glimepiride** is a **sulfonylurea** that stimulates insulin release from pancreatic beta cells. - This mechanism often leads to **weight gain** due to increased insulin levels. *Repaglinide* - **Repaglinide** is a **meglitinide**, which, like sulfonylureas, increases insulin secretion in a glucose-dependent manner. - This increased insulin secretion can also result in **weight gain**. *Gliclazide* - **Gliclazide** is another **sulfonylurea** that works by increasing insulin secretion from the pancreas. - Similar to other sulfonylureas, its use is commonly associated with **weight gain**.

Q: Which sulfonylurea is used in the treatment of neurogenic diabetes insipidus?

Chlorpropamide. ***Chlorpropamide*** - **Chlorpropamide** is the only sulfonylurea that has an **antidiuretic effect** and can enhance the action of **antidiuretic hormone (ADH)** by increasing the release of ADH and potentiating its action on the renal tubules. - This effect makes it useful in some cases of partial **neurogenic diabetes insipidus**, where there's still some ADH production. *Glyburide* - **Glyburide** is a second-generation sulfonylurea primarily used for **type 2 diabetes mellitus** to increase insulin secretion. - It does not have significant **antidiuretic properties** that would be beneficial in diabetes insipidus. *Glipizide* - **Glipizide** is another second-generation sulfonylurea, similar to glyburide, primarily used to stimulate **insulin release** from pancreatic beta cells in **type 2 diabetes**. - It lacks the specific mechanism of action required to treat **diabetes insipidus**. *Tolbutamide* - **Tolbutamide** is a first-generation sulfonylurea that also works by stimulating **insulin secretion** from the pancreas. - While it is a sulfonylurea, it does not possess the unique **antidiuretic properties** of chlorpropamide that are required for treating diabetes insipidus.

Q: What is the most common gastrointestinal side effect of oral contraceptives?

Nausea. ***Nausea*** - **Nausea** is a very common gastrointestinal side effect of oral contraceptives, especially during the initial weeks of use, due to the **estrogen component**. - This side effect often **improves over time** as the body adjusts, or can be managed by taking the pill with food or at bedtime. *Weight loss* - Oral contraceptives are **not typically associated with weight loss**; in fact, some users may experience slight weight gain, although studies show no consistent significant effect. - Changes in weight are more often due to **fluid retention** rather than true fat loss. *Decreased appetite* - **Decreased appetite** is not a common side effect of oral contraceptives; rather, some individuals might experience an increased appetite due to hormonal fluctuations. - The hormonal effects on metabolism and appetite are **varied and not consistently demonstrated** to lead to decreased appetite. *Constipation* - **Constipation** is not a frequent gastrointestinal side effect of oral contraceptives; rather, some users may experience changes in bowel habits, but **diarrhea is more commonly reported** than constipation when GI issues occur. - Hormonal contraceptives primarily affect the gut through **estrogen and progestin**, leading to various effects, but constipation is not a predominant one.

Q: Ergometrine is contraindicated in:

Eclampsia. ***Eclampsia*** - Ergometrine is an **ergot alkaloid** that causes generalized **vasoconstriction**, which can lead to a dangerous increase in blood pressure. - In a patient with **eclampsia** (characterized by hypertension, proteinuria, and seizures), this vasoconstriction can worsen **hypertension** and increase the risk of **stroke, seizures, or cardiac events**, making it an absolute contraindication. - **Pre-eclampsia and severe hypertension** are also contraindications for the same reason. *Induction of labour* - Ergometrine is **absolutely contraindicated during active labor** because it causes **tetanic (sustained, continuous) uterine contractions** rather than the coordinated contractions needed for delivery. - These sustained contractions can cause **fetal hypoxia** (due to impaired placental blood flow), **uterine rupture**, and **fetal distress**. - It is used only **after delivery of the baby** (third stage of labor) to contract the uterus and prevent postpartum hemorrhage. *Abortion* - Ergometrine can be used in cases of **incomplete abortion** to help contract the uterus and expel retained products of conception, thereby reducing blood loss. - It is not contraindicated in abortion management when used appropriately under medical supervision. *Post partum hemorrhage* - Ergometrine is a **first-line agent for the prevention and treatment of postpartum hemorrhage** because it effectively contracts the uterus, reducing blood loss. - Its ability to induce strong, sustained uterine contractions makes it highly effective in this setting, unless there are specific contraindications like **severe hypertension or eclampsia**.

Q: All of the following statements regarding metformin are true, except:

Acts by increasing insulin secretion. ***Acts by increasing insulin secretion*** - Metformin primarily acts by decreasing **hepatic glucose production** and increasing **insulin sensitivity** in peripheral tissues. - It does not directly stimulate insulin secretion from pancreatic beta cells, unlike sulfonylureas. *It causes little or no hypoglycemia in non diabetic subjects* - Metformin is considered a **euglycemic agent** because it rarely causes hypoglycemia when used as monotherapy, even in non-diabetic individuals. - Its mechanism of action primarily involves reducing glucose output from the liver and improving insulin action, rather than overtly lowering blood sugar. *When given with alcohol, increases risk of lactic acidosis* - Co-administration of metformin with alcohol significantly increases the risk of **lactic acidosis**, especially in patients with pre-existing renal impairment or liver disease. - Both metformin and alcohol can impair lactate metabolism, leading to its accumulation in the bloodstream. *Increases peripheral utilisation of glucose and decreases absorption of glucose from intestine* - Metformin **enhances glucose uptake and utilization** in peripheral tissues, particularly skeletal muscle, by improving insulin sensitivity. - It also has a minor effect on the gastrointestinal tract, causing a **modest decrease in glucose absorption** from the intestine, contributing to its overall glucose-lowering effect.

Q: Which of the following statements about acarbose is incorrect?

It does not delay the progression of diabetes.. Phase 1: it does not delay the progression of diabetes - This statement is **incorrect** - clinical studies, particularly the **STOP-NIDDM trial**, have demonstrated that acarbose **can delay the progression from impaired glucose tolerance (IGT) to type 2 diabetes**. - Acarbose's mechanism of reducing postprandial glucose fluctuations helps in **beta-cell preservation** and improves insulin sensitivity, thereby modifying disease progression. - This is a well-established benefit of acarbose beyond just glycemic control. *It is an alpha-glucosidase inhibitor* - This is a **correct** statement - acarbose is indeed an **alpha-glucosidase inhibitor** that works in the small intestine [1]. - It inhibits enzymes that break down complex carbohydrates, thereby delaying glucose absorption and reducing postprandial glucose spikes [1], [3]. *It decreases fibrinogen levels* - While acarbose does not have a **direct, primary pharmacological effect** on fibrinogen levels, this statement is debatable. - Improved glycemic control with any antidiabetic agent can have indirect effects on various cardiovascular markers over time. - However, decreasing fibrinogen is not a recognized clinical indication or primary mechanism of acarbose [2]. *Controls both pre and post prandial hyperglycemia* - This is largely **correct** - acarbose is most effective at controlling **postprandial hyperglycemia** by delaying carbohydrate digestion and absorption [3]. - While its primary and strongest effect is on post-meal glucose spikes, improved overall glycemic control can contribute to modest improvements in fasting glucose levels as well.

Q: All of the following are uses of octreotide except for which of the following?

Hepatic encephalopathy. ***Hepatic encephalopathy*** - **Octreotide is not typically used for hepatic encephalopathy**. Treatment focuses on reducing ammonia levels, often with **lactulose** or **rifaximin**. - Its mechanism of action (somatostatin analog) does not directly address the pathophysiology of hepatic encephalopathy. *Secretory diarrhea* - Octreotide is highly effective in treating **secretory diarrhea**, especially in cases related to tumors such as **VIPomas** or **carcinoid syndrome** [1, 2]. - It reduces intestinal fluid and electrolyte secretion by mimicking the action of **somatostatin**. *Acromegaly* - Octreotide is a primary treatment for **acromegaly**, a condition caused by excessive growth hormone production [1, 2]. - It suppresses the secretion of **growth hormone (GH)** and **insulin-like growth factor 1 (IGF-1)** from the pituitary gland [1, 2]. *Bleeding esophageal varices* - Octreotide is used to manage acute bleeding from **esophageal varices** by causing splanchnic vasoconstriction [1, 2]. - This action reduces **portal venous pressure**, thereby decreasing blood flow to the varices and stemming the hemorrhage.

Question 1

Intranasal calcitonin is used for:

Accepted Answer

Osteoporosis (Post-menopausal)

Answer

Osteoporosis (Senile)

Answer

Paget's disease

Answer

Hypercalcemia

Question 2

What is the longest-acting insulin?

Accepted Answer

Degludec insulin

Answer

Insulin-zinc suspension

Answer

Protamine-zinc insulin

Answer

Neutral protamine Hagedorn (NPH)

Question 3

Which of the following drugs used to treat type II diabetes mellitus causes weight loss?

Accepted Answer

Metformin

Answer

Glimepiride

Answer

Repaglinide

Answer

Gliclazide

Question 4

Which sulfonylurea is used in the treatment of neurogenic diabetes insipidus?

Accepted Answer

Chlorpropamide

Answer

Glyburide

Answer

Glipizide

Answer

Tolbutamide

Question 5

Which antidiabetic medication is safe in both liver and renal failure?

Accepted Answer

Linagliptin

Answer

None of the options

Answer

Insulin

Answer

Both

Question 6

What is the most common gastrointestinal side effect of oral contraceptives?

Accepted Answer

Nausea

Answer

Decreased appetite

Answer

Weight loss

Answer

Constipation

Question 7

Ergometrine is contraindicated in:

Accepted Answer

Eclampsia

Answer

Induction of labour

Answer

Post partum hemorrhage

Answer

Abortion

Question 8

All of the following statements regarding metformin are true, except:

Accepted Answer

Acts by increasing insulin secretion

Answer

It causes little or no hypoglycemia in non diabetic subjects

Answer

When given with alcohol, increases risk of lactic acidosis

Answer

Increases peripheral utilisation of glucose and decreases absorption of glucose from intestine

Question 9

Which of the following statements about acarbose is incorrect?

Accepted Answer

It does not delay the progression of diabetes.

Answer

It is an alpha-glucosidase inhibitor.

Answer

Controls both pre and post prandial hyperglycemia.

Answer

It decreases fibrinogen levels.

Question 10

All of the following are uses of octreotide except for which of the following?

Accepted Answer

Hepatic encephalopathy

Answer

Secretory diarrhea

Answer

Acromegaly

Answer

Bleeding esophageal varices

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?